Black Patients Have Similar Immune Checkpoint Inhibitor Effectiveness, Lower Toxicity
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 5, 2024 -- Black patients have similar immune checkpoint inhibitor (ICI) effectiveness and lower toxicities compared with White patients, according to a study published online Nov. 14 in The Lancet Oncology.
Sean Miller, M.D., from the Veterans Affairs Ann Arbor Healthcare System in Michigan, and colleagues conducted a retrospective cohort study to characterize the effectiveness and safety of ICIs in Black patients. All patients in the U.S. Veterans Health Administration system Corporate Data Warehouse who self-identified as non-Hispanic Black or African American or non-Hispanic White and received PD-1, PD-L1, CTLA-4, or LAG-3 inhibitors between Jan. 1, 2010, and Dec. 31, 2023, were included.
Data were included for 26,398 patients: 18.7 percent Black and 81.3 percent White. The researchers found that Black patients had longer time to treatment discontinuation compared with White patients (two-year unadjusted rates, 10.7 versus 8.6 percent; adjusted hazard ratio, 0.91); similar time to next treatment (23.5 versus 25.6 percent for White patients); and slightly improved overall survival (36.5 versus 36.5 percent for Black versus White patients; hazard ratio, 0.95). Black patients had a reduced risk for all-grade immune-related adverse events compared with White patients; immune-related adverse events requiring treatment with systemic steroids; and immune-related adverse events resulting in permanent ICI discontinuation (adjusted hazard ratios, 0.75, 0.61, and 0.58, respectively).
"To our knowledge, this study is the largest analysis of ICI efficacy and safety in Black patients to date, a population severely under-represented in ICI clinical trials, and raises crucial questions regarding the reasons for lower observed immune-related adverse events than in White patients," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.